drugset / Trial / NCT05268237
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
RandomizedSequentialDouble-blindTreatment
Summary
This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).
Timeline
- Start
- 2023-04-25
- Primary completion
- 2025-12
- Completion
- 2026-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 3 mg | Other |
| Subject | Liraglutide | Peptide | 12 mg | Other |
| Subject | Liraglutide | Peptide | 30 mg | Other |